Bvf Inc Cogent Biosciences, Inc. Transaction History

Bvf Inc

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$10.65 - $14.84 $11.7 Million - $16.3 Million	-1,100,000 Reduced 52.76%	984,824 $11.4 Million
Q3 2022 Nov 14, 2022	SELL	$9.39 - $16.99 $1.62 Million - $2.93 Million	-172,350 Reduced 7.64%	2,084,824 $31.1 Million
Q2 2022 Aug 15, 2022	BUY	$3.92 - $9.73 $2.84 Million - $7.05 Million	724,892 Added 47.31%	2,257,174 $20.4 Million
Q4 2020 Feb 12, 2021	BUY	$9.04 - $13.01 $13.9 Million - $19.9 Million	1,532,282 New	1,532,282 $17.2 Million

173

114M

56.7K

40.4K

Ticker COGT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,758,300
Market Cap $549M
Description
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found ...

Get notified when there are updates to the investment portfolio of Bvf Inc, based on Form 13F filings with the SEC.

Stay updated on Bvf Inc with notifications on news.